SPOREs
Ovarian
Ovarian SPOREDF/HCC's Ovarian Cancer SPORE enters its final year of its first five years of funding. Funding for an additional five years will require that the renewal application we submitted in September receives a successful review. This “Competing Continuation” application described our progress in the previous four years and set forth our vision for ovarian cancer research for the next five years. Progress included more than 60 publications and nearly 40 grants received by SPORE investigators. Scientific advances included progress on identifying modifiable risk factors for ovarian cancer (including bolstering the biologic case against talc as cause of ovarian cancer), establishing that the fimbirated end of the Fallopian tubes may be the source of the most lethal type of ovarian cancer, spearheading the first trial of ovarian cancer screening biomarkers in pre-diagnostic specimens from the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial as well as the first inter-SPORE trial of intraperitoneal Avastin, and beginning our own local trial of an immunologic therapy involving a vaccine that fuses a patient’s immune (dendritic cells) with her cancer cells. Our vision for ovarian cancer research for the next five years includes projects that will capitalize on the advances we have made and address the full range of prevention, early detection, and treatment of ovarian cancer. |
